Literature DB >> 6325058

Gc (vitamin D binding protein) binds to cytoplasm of all human lymphocytes and is expressed on B-cell membranes.

M Petrini, R M Galbraith, P A Werner, D L Emerson, P Arnaud.   

Abstract

Peripheral blood lymphocytes were examined immunohistologically for evidence of interactions with Gc protein, a major vitamin D binding protein in serum. In the cytoplasm, binding sites for purified Gc were readily detectable in all cells, and these sites were only partially occupied by Gc. In contrast, on the membrane of viable cells, there was negligible evidence of binding of either the apo- or holoform of Gc protein, but substantial quantities of firmly bound immunoreactive endogenous Gc were detected. Separation experiments and double-label fluorescence with antisera recognizing defined phenotypic markers showed immunoreactive membrane Gc on 30-40% of unfractionated mononuclear cells and greater than 95% of monocytes or B cells. Only 5-8% of T cells were similarly reactive; these were not apparently confined to any given subset. Extraction of unfractionated cells with 6 M urea or solubilization in Nonidet P-40 released immunoreactive Gc protein, with physicochemical properties indistinguishable from those of Gc purified from serum (apparent MW 56K; pI 4.8-5.1). These findings indicate that membrane Gc may represent another surface immunofluorescence marker for B cells, and may play a role in immunocyte function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325058     DOI: 10.1016/0090-1229(84)90248-4

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  17 in total

1.  Binding of GC (VDBP) to membranes of human B lymphocytes following stripping of extant protein.

Authors:  M Petrini; A Allegrini; F Ambrogi; P Valentini; A Sabbatini; P Arnaud; R M Galbraith
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

2.  1,25-Dihydroxycholecalciferol inhibits the cochemotactic activity of Gc (vitamin D binding protein).

Authors:  M Petrini; A Azzarà; G Carulli; B Grassi; F Ambrogi; R M Galbraith
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

3.  Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Matthew T Drake; Matthew J Maurer; Cristine Allmer; Kari G Rabe; Susan L Slager; George J Weiner; Timothy G Call; Brian K Link; Clive S Zent; Neil E Kay; Curtis A Hanson; Thomas E Witzig; James R Cerhan
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

4.  Role of group-specific component (vitamin D binding protein) in clearance of actin from the circulation in the rabbit.

Authors:  P J Goldschmidt-Clermont; H Van Baelen; R Bouillon; T E Shook; M H Williams; A E Nel; R M Galbraith
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

5.  Inhibition of human natural killer activity by antiserum against vitamin D-binding protein, a group-specific component (Gc).

Authors:  T Chujo; T Machii; S Tagawa; H Kuratsune; E Ueda; H Kimura; T Kitani
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

6.  Translocation of phospholipid/Ca2+-dependent protein kinase in B-lymphocytes activated by phorbol ester or cross-linking of membrane immunoglobulin.

Authors:  A E Nel; M W Wooten; G E Landreth; P J Goldschmidt-Clermont; H C Stevenson; P J Miller; R M Galbraith
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

7.  Identification of two distinct cell binding sequences in the vitamin D binding protein.

Authors:  Jianhua Zhang; David M Habiel; Mahalakshmi Ramadass; Richard R Kew
Journal:  Biochim Biophys Acta       Date:  2010-03-06

8.  Distinct sites on the G-actin molecule bind group-specific component and deoxyribonuclease I.

Authors:  P J Goldschmidt-Clermont; R M Galbraith; D L Emerson; F Marsot; A E Nel; P Arnaud
Journal:  Biochem J       Date:  1985-06-01       Impact factor: 3.857

9.  An association between Gc (vitamin D-binding protein) alleles and susceptibility to rheumatic fever.

Authors:  G M Bahr; L J Eales; K E Nye; H A Majeed; A M Yousof; K Behbehani; G A Rook
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

10.  Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol.

Authors:  S Homma; N Yamamoto
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.